SCHEMBL7450896

SCHEMBL7450896

O=[N+]([O-])c1cccc(CNc2nc(-n3ccnc3)nc3sc4c(c23)CCCC4)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 4/20 0.53
RNASEL Q05823 1/20 0.45
HTT P42858 4/20 0.43
MAPT P10636 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
PTGS2 P35354 5/20 0.43
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
KDM4E B2RXH2 4/20 0.41
ALDH1A1 P00352 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
HSD17B10 Q99714 2/20 0.40
LMNA P02545 1/20 0.40
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5778201 0.87 RNASEL (0.45) PDE5ARNASELHTTMAPTMEN1
SCHEMBL5778490 0.86 RNASEL (0.45) PDE5ARNASELHTTMAPTMEN1
SCHEMBL5798508 0.85 PDE5A (0.57) PDE5AHTTMAPTMEN1KMT2A
SCHEMBL5781601 0.85 HTT (0.45) PDE5ARNASELHTTMAPTMEN1
SCHEMBL5129837 0.83 PDE5A (0.56) PDE5AMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL5781751 0.83 RNASEL (0.51) PDE5ARNASELHTTMAPTMEN1
SCHEMBL5777235 0.82 PRKCI (0.58) PTGS2PRKCI
SCHEMBL5801996 0.82 HTT (0.48) PDE5AHTTMAPTMEN1KMT2A
SCHEMBL7129570 0.82 HTT (0.48) PDE5AHTTMAPTMEN1KMT2A
SCHEMBL5129589 0.82 PDE5A (0.54) PDE5AMAPTMEN1KMT2APTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6432950-B1 ANTICANCER AGENTS; KILLING CANCER CELLS CELL PATHWAYS 2002-08-13 US disclosed
US-6133271-A Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives CELL PATHWAYS, INC. (US) 2000-10-17 US disclosed
US-6110920-A TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-08-29 US disclosed
EP-0920431-A1 THIENOPYRIMIDINES MERCK PATENT GmbH (DE) 1999-06-09 EP disclosed
WO-1998006722-A1 THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 1998-02-19 WO disclosed